6975-75-3
6975-75-3
Chemical Structure
ILK-IN-3
- CAS No.: 6975-75-3
- Formula:C10H12N6O
- Molecular Weight:232.24
IUPAC Name: (E)-4-((4-methoxyphenyl)diazenyl)-1H-pyrazole-3,5-diamine
InChIKey: QNRNTYHAOBVOKW-BUHFOSPRSA-N
SMILES: NC1=NNC(N)=C1/N=N/C2=CC=C(OC)C=C2
Biological Activity: ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ILK-IN-3 | 99.62% | ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.86
HY-100429CAN508 -
Similarity Score 0.68
HY-183889p-Ethoxychrysoidin -
Similarity Score 0.64
HY-B0985Phenazopyridine hydrochloride -
Similarity Score 0.63
HY-B0985APhenazopyridine -
Similarity Score 0.62
HY-D0303AChrysoidine G -
Similarity Score 0.62
HY-D0303Chrysoidine G free base -
Similarity Score 0.62
HY-131327Azo-resveratrol -
Similarity Score 0.61
HY-W587874Disperse orange 3 -
Similarity Score 0.61
![4-[2-(4-Bromophenyl)diazenyl]phenol Chemical Structure](//file.medchemexpress.com/product_pic/hy-w013853.gif)
HY-W0138534-[2-(4-Bromophenyl)diazenyl]phenol -
Explore the MedChemAI to find more analogs
![4-[2-(4-Bromophenyl)diazenyl]phenol Chemical Structure](http://file.medchemexpress.com/product_pic/hy-w013853.gif)
References
- [1]. Jessica Kalra, et al. Validating the Use of a Luciferase Labeled Breast Cancer Cell Line, MDA435LCC6, as a Means to Monitor Tumor Progression and to Assess the Therapeutic Activity of an Established Anticancer Drug, Docetaxel (Dt) Alone or in Combination With the ILK Inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1;11(9):826-38. [Content Brief]
- [2]. Mavrogeni ME, et al. A facile consensus ranking approach enhances virtual screening robustness and identifies a cell-active DYRK1α inhibitor. Future Med Chem. 2018 Oct;10(20):2411-2430. [Content Brief]
